Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated
tau protein characterizes 80% of all dementia disorders, the most common …

Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …

Compelling experimental evidence suggests that microglial activation is involved in the spread
of tau tangles over the neocortex in Alzheimer’s disease (AD). We tested the hypothesis …

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…

Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …

Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …